

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

2024 FIRST QUARTERLY REPORT

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) to provide shareholders of the Company and the public with the updated financial information of the Company. This announcement is also published on the website of the Shanghai Stock Exchange simultaneously.

The unaudited results (the “**First Quarterly Report**”) of the Group for the three months ended 31 March 2024 are provided. The financial information contained in the First Quarterly Report was prepared in accordance with the Chinese Accounting Standards for Business Enterprises (“**CASs**”), and consists accounting data which has not been audited. Potential investors and shareholders of the Company are advised to pay attention to the underlying investment risks.

The First Quarterly Report is written in both Chinese and English. In the case of any discrepancies, the Chinese version of the First Quarterly Report shall prevail.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Chairman
Shi Wenling

Beijing, the PRC, 29 April 2024

As at the date of this announcement, the executive Directors of the Company are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Ms. Yao Lijie, Mr. Wong Tak Shing and Mr. Weng Jie.

* *For identification purposes only*

A Share Securities Code: 688236

H Share Securities Code: 01858

Stock Short Name: Chunli Medical

Beijing Chunlizhengda Medical Instruments Co., Ltd.* 2024 First Quarterly Report

The Board of Directors of the Company and all Directors undertake that this announcement contains no false record, misleading statement or material omission, and assume legal responsibility for the truthfulness, accuracy and completeness of its contents in accordance with law.

Important Notice

The Board of Directors of the Company, the Board of Supervisors, the Directors, Supervisors, senior management warrant that the content of this quarterly report is true, accurate and complete and contains no false record, misleading statement or material omission, and jointly and severally assume legal responsibility for the content of this report.

The person in charge of the Company, the person in charge for accounting affairs of the Company and the person in charge of the accounting department (financial controller) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.

Whether the financial statements for the first quarter are audited?

Yes No

1. Key financial data

(A) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

Items	Current Reporting Period	Percentage change of the Current
-------	--------------------------	----------------------------------

2024 First Quarterly Report

			Reporting Period as compared to the corresponding period of last year (%)
Revenue		221,850,180.79	-9.95
Net profit attributable to the shareholders of the listed company		55,199,616.28	-1.18
Net profit attributable to the shareholders of the listed company after deducting non-recurring profit or loss		48,882,462.10	-1.46
Net cash flows generated from operating activities		-129,613,339.07	N/A
Basic earnings per share (yuan/share)		0.14	-6.67
Diluted earnings per share (yuan/share)		0.14	-6.67
Weighted average RONA (%)		1.90	Decrease by 0.13 percentage points
Total investments in research and development		34,991,868.71	5.17
Percentage of research and development investment to revenue (%)		15.77	Increase by 2.26 percentage points
	At the end of Current Reporting Period	At the end of last year	Percentage change at the end of this Reporting Period as compared to the

2024 First Quarterly Report

			end of last year (%)
Total assets	3,542,662,190.69	3,649,560,924.88	-2.93
Owners' equity attributable to the shareholders of the listed company	2,932,666,469.62	2,877,466,853.34	1.92

(B) Non-recurring profit or loss items and amounts

√Applicable Non applicable

Unit: Yuan Currency: RMB

Non-recurring Profit or Loss	Amount for the Period	Description
Gain and loss from disposal of non-current assets, including the part written off for provision for impairment on assets		
Government grants included in profit or loss for the current period other than those closely relating to the normal business of enterprises and having continuous impact on profit or loss of the Company under certain standard and in compliance with national policies	2,607,636.22	
Gains or losses on changes in fair value arising from financial assets and liabilities held by non-financial enterprises and gains or losses on disposal of financial assets and liabilities, except for effective hedging activities related to normal operations of the Company	3,988,436.06	
Capital utilization fee received from non-financial enterprises included in current profit or loss		
Gain or loss on entrusted investments or assets under management		
Gain or loss on entrusted loans		
Loss on assets due to force majeure events, such as natural disasters		

Reversal of the impairment provision for receivables under independent impairment test		
Investments of subsidiaries, associates and joint ventures in which the investment cost was less than the profit at fair value of identifiable net assets of the investees at the time of acquisition		
Net gains or losses of subsidiaries for the current period from the beginning of the period to the date of consolidation arising from business consolidation under common control		
Gain or loss on exchange of non-monetary assets		
Gain or loss on debt restructuring		
One-off expenses incurred by enterprises due to the discontinuity of relevant business activities, such as staff resettlement expenses		
One-off effect on current profit or loss due to the adjustments to laws and regulations on tax and accounting		
One-off share-based payment expenses recognised due to cancellation and modification of share incentive scheme		
Gains or losses arising from changes in the fair value of employee benefits for cash-settled share-based payments, payable after the vesting date		
Gain or loss arising from changes in fair value of investment properties under fair value method on subsequent measurement		
Gain on transactions at unfair trading prices		
Gain or loss from other contingencies which are not related to the Company's normal operations		
Custody fee income from custody operations		

2024 First Quarterly Report

Other non-operating income and expenses apart from the aforesaid items	835,873.81	
Other gain or loss items conforming to the definition of non-recurring gains or losses		
Less: Effect of income tax	1,114,791.91	
Impact of minority interests (after tax)		
Total	6,317,154.18	

Reasons should be given for the Company defining the non-recurring gain or loss items with significant amount not set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public - Non-recurring Gains or Losses along with non-recurring profit or loss items set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public - Non-recurring Profit or Loss as recurring gain or loss items.

Applicable Not applicable

Unit: Yuan Currency: RMB

Item	Amount involved	Reason(s)
Additional value-added tax deduction for advanced manufacturing	709,638.69	Continuous impact on gains or losses of the Company
Government grants related to assets	647,762.94	Continuous impact on gains or losses of the Company

(C) Description and reasons for the changes in key accounting data and financial indicators

Applicable Not applicable

2. Information of shareholders

(A) Total number of ordinary shareholders, preferred shareholders whose voting rights have been reinstated, and the shareholding of top ten shareholders

Unit: Share

Total number of ordinary shareholders at the end of the Reporting Period		6,133	Total number of shareholders of preferred shares with voting rights reinstated (if any) at the end of the Reporting Period	0			
Shareholding of top ten shareholders (excluding lending shares through securities financing)							
Name of shareholder	Nature of shareholder	Number of shares held	Shareholding percentage (%)	Number of shares held subject to trading restrictions	Number of Shares subject to trading restrictions that include lending shares for securities financing	Shares charged, tagged or frozen	
						Status of shares	Number
Shi Chunbao	Domestic natural person	114,840,685	29.94	113,685,435	113,685,435	None	0
Yue Shujun	Domestic natural person	95,447,900	24.88	95,447,900	95,447,900	None	0
HKSCC Nominees Limited ^(Note)	Overseas legal person	95,125,175	24.80	0	0	Unknown	-

2024 First Quarterly Report

Beijing Panmao Investment Management Co., Ltd. - Panmao (Shanghai) Investment Center (LLP)	Domestic non-state owned legal person	17,250,000	4.50	0	0	Unknown	-
China Bohai Bank Co., Ltd - China Securities Healthcare Reform Flexible Allocation Hybrid Securities Investment Fund	Domestic non-state owned legal person	5,350,039	1.39	0	0	Unknown	-
Hong Kong Securities Clearing Company Limited	Overseas legal person	2,644,111	0.69	0	0	Unknown	-
Huang Dong	Domestic natural person	2,533,335	0.66	0	0	Unknown	-
Beijing Panmao Investment Management Co., Ltd. - Panmao (Shanghai) Investment Center (LLP)	Domestic non-state owned legal person	2,500,000	0.65	0	0	Unknown	-
China Life Insurance Company Limited - Traditional - General Insurance Products - 005L - CT001 Shanghai	Domestic non-state owned legal person	2,480,773	0.65	0	0	Unknown	-
Jin Jie	Domestic natural person	2,123,759	0.55	0	0	Unknown	-
Shareholding of top ten shareholders not subject to trading restrictions							
Name of shareholder	Number of tradable shares held not subject to trading restrictions	Share class and number					
		Share class	Number				
HKSCC Nominees Limited ^(Note)	95,125,175	Overseas listed foreign shares	95,125,175				
Beijing Panmao Investment Management Co., Ltd. - Panmao (Shanghai) Investment Center (LLP)	17,250,000	RMB-denominated ordinary shares	17,250,000				

2024 First Quarterly Report

China Bohai Bank Co., Ltd - China Securities Healthcare Reform Flexible Allocation Hybrid Securities Investment Fund	5,350,039	RMB-denominated ordinary shares	5,350,039
Hong Kong Securities Clearing Company Limited	2,644,111	RMB-denominated ordinary shares	2,644,111
Huang Dong	2,533,335	RMB-denominated ordinary shares	2,533,335
Beijing Panmao Investment Management Co., Ltd. - Panmao (Shanghai) Investment Center (LLP)	2,500,000	RMB-denominated ordinary shares	2,500,000
China Life Insurance Company Limited - Traditional - General Insurance Products - 005L - CT001 Shanghai	2,480,773	RMB-denominated ordinary shares	2,480,773
Jin Jie	2,123,759	RMB-denominated ordinary shares	2,123,759
Longwin Asset Management Co., Ltd. - Longwin Healthcare Preferred Phase 1 Private Securities Investment Fund* (龍贏醫療健康優選1期私募證券投資基金)	2,024,861	RMB-denominated ordinary shares	2,024,861
Industrial and Commercial Bank of China Limited - China-Europe Medical and Health Hybrid Securities Investment Fund	2,001,114	RMB-denominated ordinary shares	2,001,114

Description of connected relationship or acting in concert of the above shareholders	1. As of the date of this report, Shi Chunbao and Yue Shujun are couple, Panmao and Panxin are the same controlling party. Apart from the above, the Company does not receive any statement from the top ten shareholders regarding the existence of connected relationship or agreement of acting-in-concert; 2. The Company is not aware of the existence of connected relationship among shareholders of tradable shares, or if they are the concerted parties under the stipulation of Measures for the Administration of Disclosure of Shareholder Equity Changes of Listed Companies.
Description on participation in margin financing and securities lending and lending shares for securities financing by top ten shareholders and top ten shareholders not subject to trading restrictions (if any)	None

As of the end of the Reporting Period, the total number of ordinary shareholders of the Company amounted to 6,133, of which 6,116 holders of A Shares and 17 holders of H Shares;

Note: HKSCC NOMINEES LIMITED refers to Hong Kong Securities Clearing Company (Nominees) Limited, which held shares on behalf of customers. As there is no requirements by the relevant rules of the Hong Kong Stock Exchange for customers to declare whether the shares they held got pledged or frozen, Hong Kong Securities Clearing Company (Nominees) Limited is unable to calculate or provide the number of shares pledged or frozen.

The total number of shares held by Mr. Shi Chunbao includes H Shares that are not subject to sale.

Lending of shares by shareholders involved in the securities financing business holding more than 5% of the shares, top 10 shareholders and top 10 shareholders of tradable shares not subject to trading restrictions

Applicable Not applicable

The changes of the top 10 shareholders and the top 10 shareholders of tradable shares not subject to trading restrictions resulted from lending/repayment for securities financing compared with the previous period

Applicable Not applicable

3. Other notice

Other important information related to the operational conditions of the Company during the Reporting Period which requires the attention of the investors

Applicable Not applicable

4. Quarterly financial statements

(A) Type of auditor' s opinion

Applicable Not applicable

(B) Financial statements

CONSOLIDATED BALANCE SHEET

31 March 2024

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	31 March 2024	31 December 2023
Current assets:		
Monetary funds	1,220,478,879.78	1,266,367,522.67
Settlement reserve		
Placements with banks and non-bank financial institutions		
Held-for trading financial assets	741,195,087.52	832,019,095.90
Derivative financial assets		
Notes receivable	9,908,652.48	35,825,458.71
Accounts receivable	418,285,561.50	405,895,527.39
Accounts receivable financing		
Prepayment	12,844,375.54	10,802,201.19
Premium receivable		
Reinsurance premium receivables		
Reserves for reinsurance contract receivables		
Other receivables	382,251.17	348,800.03

2024 First Quarterly Report

Including: Interests receivables		
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	476,158,025.23	434,485,725.70
Including: Data resources		
Contract assets		
Assets held- for-sale		
Non-current assets due within one year		
Other current assets	20,248,555.74	19,615,485.87
Total current assets	2,899,501,388.96	3,005,359,817.46
Non-current assets:		
Loans and advances		
Debt investments		
Other debt investments		
Long-term receivables		
Long-term equity investments		
Other investments in equity instruments		
Other non- current financial assets		
Investment property		

2024 First Quarterly Report

Fixed assets	313,724,732.95	312,930,579.87
Construction in progress	151,983,823.45	150,138,063.04
Productive biological assets		
Oil & gas assets		
Right-of-use assets	1,768,029.03	2,065,991.49
Intangible assets	133,622,900.88	136,270,839.38
Including: Data resources		
Development expenditures		
Including: Data resources		
Goodwill	13,359,553.09	13,359,553.09
Long-term prepayments		
Deferred income tax assets	27,766,307.29	27,631,861.33
Other non-current assets	935,455.04	1,804,219.22
Total non-current assets	643,160,801.73	644,201,107.42
Total assets	3,542,662,190.69	3,649,560,924.88
Current liabilities:		
Short-term borrowings		
Borrowings from central banks		
Placements from banks and non-bank financial institutions		
Held-for-trading financial liabilities		
Derivative financial liabilities		

2024 First Quarterly Report

Notes payable		
Accounts payable	206,180,640.00	225,500,169.91
Advances received		
Contract liabilities	97,813,557.11	149,563,275.39
Financial assets sold under repurchase agreement		
Deposits and placements from peers		
Brokerage for trading securities		
Brokerage for underwriting securities		
Employee remuneration payable	31,906,456.62	89,719,385.48
Taxes payable	35,621,462.63	61,519,271.32
Other payables	64,615,577.07	66,314,036.00
Including: Interests payable		
Dividends payable		
Handling fee and commission payables		
Reinsurance premium payables		
Held-for-sale liabilities		
Non-current liabilities due within one year	1,221,386.17	1,221,386.17
Other current liabilities	77,332,137.45	82,835,311.24

2024 First Quarterly Report

Total current liabilities	514,691,217.05	676,672,835.51
Non-current liabilities:		
Reserves for insurance contracts		
Long-term borrowings		
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	549,909.32	531,543.62
Long-term payables		
Long-term employee remuneration payable		
Estimated liabilities		
Deferred income	83,802,703.55	83,790,835.82
Deferred income tax liabilities	9,330,276.98	9,330,276.98
Other non-current liabilities		
Total non-current liabilities	93,682,889.85	93,652,656.42
Total liabilities	608,374,106.90	770,325,491.93
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	383,568,500.00	383,568,500.00
Other equity instruments		
Including: Preferred shares		

2024 First Quarterly Report

Perpetual bonds		
Capital reserve	1,044,799,419.83	1,044,799,419.83
Less: treasury shares		
Other comprehensive income		
Specific reserve		
Surplus reserve	181,585,925.26	181,585,925.26
General reserve		
Undistributed profits	1,322,712,624.53	1,267,513,008.25
Total equity attributable to owners (or equity attributable to shareholders) of the parent company	2,932,666,469.62	2,877,466,853.34
Minority interests	1,621,614.17	1,768,579.61
Total owners' equity (or shareholders' equity)	2,934,288,083.79	2,879,235,432.95
Total liabilities and owners' equity (or shareholders' equity)	3,542,662,190.69	3,649,560,924.88

Person in charge of the Company: Shi Wenling; Person in charge for accounting affairs of the Company: Li Yumei; Person in charge of the accounting department: Li Yumei

Consolidated income statement

January to March 2024

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First quarter of 2024	First quarter of 2023
1. Total operating revenue	221,850,180.79	246,355,024.32
Including: Operating revenue	221,850,180.79	246,355,024.32
Interest income		

2024 First Quarterly Report

Premiums gained		
Income from handling fee and commission		
2. Total operating cost	164,450,441.62	183,535,965.29
Including: Operating cost	58,041,719.59	77,916,277.20
Interest expense		
Handling fee and commission expense		
Surrender value		
Net amount of compensation payout		
Net amount of insurance contracts reserves withdrawn		
Policy dividend payment		
Reinsurance Expenses		
Taxes and surcharge	1,832,378.18	1,531,930.76
Selling expenses	63,145,976.61	64,965,051.80
Administrative expenses	7,522,645.72	7,051,031.67
Research and development expenses	34,991,868.71	33,270,315.66
Financial expenses	-1,084,147.19	-1,198,641.80
Including: Interest expenses		
Interest income	1,263,505.11	1,376,795.09
Add: Other gains	2,736,455.16	2,325,447.30
Investment income (losses are presented as “-”)	3,286,525.21	3,125,700.82
Including: Investment income from associates and joint ventures		
Gains from derecognition of financial assets measured at amortised cost		
Foreign exchange gains (losses are presented as “-”)		
Net profit on hedging exposure (losses are presented as “-”)		
Gains on changes of fair value (losses are presented as “-”)	1,380,799.84	2,022,556.16
Loss on credit impairment (losses are presented as “-”)	-5,451,806.83	-7,825,220.59
Loss on asset impairment (losses are presented as “-”)	-26,245.26	-125,870.82
Gains on disposal of assets (losses are presented as “-”)		

2024 First Quarterly Report

3. Operating profit (losses are presented as “ - ”)	59,325,467.29	62,341,671.90
Add: Non-operating income	856,134.36	83,435.56
Less: Non-operating expenses	17,033.00	200,028.67
4. Gross profit (total losses are presented as “ - ”)	60,164,568.65	62,225,078.79
Less: income tax expenses	5,057,505.44	6,363,674.74
5. Net profit (net losses are presented as “ - ”)	55,107,063.21	55,861,404.05
(A) Classified by continuity of operation		
1. Net profit for continuing operation (net losses are presented as “ - ”)	55,107,063.21	55,861,404.05
2. Net profit for ceased operation (net losses are presented as “ - ”)		
(B) Classified by ownership		
1. Net profit attributable to the shareholders of the parent company (net losses are presented as “ - ”)	55,199,616.28	55,861,404.05
2. Non-controlling shareholders' profit or loss (net losses are presented as “ - ”)	-92,553.07	
6. Net other comprehensive income after tax		
(I) Net other comprehensive income after tax attributable to the owners of the parent company		
1. Other comprehensive income that cannot be reclassified into profit or loss		
(1) Changes in remeasurement on defined benefit plan		
(2) Other comprehensive income that cannot be transferred to profit and loss under equity method		
(3) Fair value change on other investments in equity instruments		
(4) Fair value change on credit risk of the enterprise		
2. Other comprehensive income that will be reclassified into profit or loss		

(1) Other comprehensive income that can be transferred to profit and loss under equity method		
(2) Fair value change on other debt investments		
(3) Amounts of financial assets reclassified into other comprehensive income		
(4) Provision on credit impairment on other debt investments		
(5) Reserves of cash flow hedging		
(6) Translation difference on financial statements denominated in foreign currencies		
(7) Others		
(II) Net other comprehensive income after tax attributable to non-controlling shareholders		
7. Total comprehensive income	55,107,063.21	55,861,404.05
(A) Total comprehensive income attributable to the owners of the parent company	55,199,616.28	55,861,404.05
(B) Total comprehensive income attributable to non-controlling shareholders	-92,553.07	
8. Earnings per share:		
(A) Basic earnings per share (yuan/share)	0.14	0.15
(B) Diluted earnings per share (yuan/share)	0.14	0.15

For business combination under common control conducted during the current period, the acquiree achieved a net profit of RMB0.00 before the combination; the acquiree achieved a net profit of RMB0.00 during the previous period.

Person in charge of the Company: Shi Wenling; Person in charge for accounting affairs of the Company: Li Yumei; Person in charge of the accounting department: Li Yumei

Consolidated cash flow statement

January to March 2024

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First quarter of 2024	First quarter of 2023
1. Cash flows from operating activities:		
Cash receipts from sale of goods and rendering of services	211,271,503.82	210,243,130.70
Net increase in the amounts of deposits from customers and placements from peers		
Net increase in amounts due to central banks		
Net increase in placements from other financial institutions		
Cash received from the premium of original insurance contract		
Net cash received from reinsurance business		
Net increase in policyholder deposits and amount for investment		
Cash received from interest, handling fee and commission		
Net increase in placements from banks and non-bank financial institutions		
Net increase in capital on business repurchased		
Net cash received on securities dealing agency services		
Receipts of tax refund		
Other cash receipts related to operating activities	6,154,227.49	2,559,428.25
Subtotal of cash inflow from operating activities	217,425,731.31	212,802,558.95
Cash payments for goods purchased and services received	113,299,416.02	95,171,085.14
Net increase in loans and advances from customers		
Net increase in amounts deposited in central bank and peers		
Cash payment on compensation payout in original insurance contract		

2024 First Quarterly Report

Net increase in placements with banks and non-bank financial institutions		
Cash payment on interest, handling fee and commission		
Cash payment for policy dividend		
Cash paid to and on behalf of employees	93,446,152.89	72,383,883.08
Taxes paid	42,675,687.92	39,103,604.16
Other cash payments related to operating activities	97,617,813.55	126,341,560.85
Subtotal cash outflow from operating activities	347,039,070.38	333,000,133.23
Net cash flows from operating activities	-129,613,339.07	-120,197,574.28
2. Cash flows from investing activities:		
Cash received from disinvestments	831,300,000.00	765,000,000.00
Cash received from return on investments	5,491,333.43	6,181,481.64
Net cash received from the disposal of fixed assets, intangible assets and other long-term assets	437,732.49	
Net cash received from the disposal of subsidiaries and other business units		
Other cash receipts related to investing activities		
Subtotal of cash inflow from investing activities	837,229,065.92	771,181,481.64
Cash paid for acquiring fixed assets, intangible assets and other long-term assets	13,500,759.37	1,025,917.03
Cash payments for investments	740,000,000.00	759,000,000.00
Net increase in pledged loans		
Net cash payments for acquisitions of subsidiaries and other business units		9,604,318.34
Other cash payments related to investing activities		
Subtotal of cash outflow from investing activities	753,500,759.37	769,630,235.37
Net cash flows from investing activities	83,728,306.55	1,551,246.27
3. Cash flows from financing activities:		
Cash received from investments		
Including: cash received by subsidiaries from non-controlling shareholders' investments		
Cash received from borrowings		
Other cash receipts related to financing activities		

2024 First Quarterly Report

Subtotal of cash inflow from financing activities		
Cash repayment of debts		
Cash paid for distribution of dividends, profits or for interest expenses		
Including: dividends and profit paid by subsidiaries to non-controlling shareholders		
Other cash payments related to financing activities		202,693.04
Subtotal of cash outflow from financing activities		202,693.04
Net cash flows from financing activities		-202,693.04
4. Effect of foreign exchange rate changes on cash and cash equivalents	-4,213.37	
5. Net increase in cash and cash equivalents	-45,889,245.89	-118,849,021.05
Add: Opening balance of cash and cash equivalents	1,266,013,075.67	957,193,661.02
6. Closing balance of cash and cash equivalents	1,220,123,829.78	838,344,639.97

Person in charge of the Company: Shi Wenling; Person in charge for accounting affairs of the Company: Li Yumei; Person in charge of the accounting department: Li Yumei

Adjustments to the financial statements at the beginning of the year of the first implementation due to the first implementation of the new accounting standards or interpretation of accounting standards since 2024

Applicable Non applicable

The Board of Directors of Beijing Chunlizhengda Medical Instruments Co., Ltd.*
30 April 2024

* For identification purposes only